"A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The striking findings showed an overall upward trend in life expectancy when patients took niraparib - a targeted therapy that blocks cancer cells from repairing their DNA when damaged - alongside the standard abiraterone acetate and prednisone treatments."
"One in four prostate cancer patients currently have limited benefits from standard hormone treatment due to a genetic mutation that can allow cancer cells to grow and mutate more rapidly, according to doctors at University College London (UCL). In the study of 696 men across 32 countries, doctors found the new drug combination led to a 37 per cent reduction in the risk of cancer growth in all patients, and a 48 per cent reduction in a subgroup of patients with the genetic mutations."
"From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging."
A trial of 696 men across 32 countries showed that adding niraparib to standard abiraterone acetate and prednisone produced an overall 37% reduction in cancer growth risk and a 48% reduction among patients with DNA-repair gene mutations. Niraparib blocks cancer cells from repairing damaged DNA. Time to symptom progression doubled with the combination therapy. One in four prostate cancer patients currently derive limited benefit from standard hormone treatment because of genetic mutations that enable faster cancer growth and mutation. The combination also showed an overall upward trend in life expectancy.
Read at www.independent.co.uk
Unable to calculate read time
Collection
[
|
...
]